Receptor News and Research

RSS

Next-generation cancer therapy shows early promise as treatment candidate for glioblastoma

A next-generation cancer therapy being developed at McMaster University has shown early promise as a treatment candidate for glioblastoma, the most aggressive and most common type of primary brain cancer in adults.

13 May 2026

Semaglutide significantly reduces obesity in treatment-resistant young adults

A weekly dose of semaglutide (2.4 mg) leads to a clinically significant reduction in body mass index (BMI) and related health outcomes in young adults with severe obesity who are treatment resistant following hospital-based non-pharmacological obesity care during childhood, according to a randomized controlled trial being presented at this year's European Congress on Obesity (ECO) in Istanbul, Turkey (12-15 May).

13 May 2026

GLP-1 obesity drugs mainly reduce fat while preserving muscle mass

New research to be presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following treatment with GLP-1 drugs for obesity, most weight loss is fat mass (80–85%) and relative muscle mass is preserved.

13 May 2026

AI-based generative framework create all-atom models of proteins in motion

Many drug and antibody discovery pathways focus on intricately folded cell membrane proteins. When molecules of a drug candidate bind to these proteins, like a key going into a lock, they trigger chemical cascades that alter cellular behavior.

13 May 2026

Once-daily orforglipron helps preserve weight loss after semaglutide or tirzepatide

Oral orforglipron helped adults maintain clinically meaningful weight loss after prior injectable tirzepatide or semaglutide therapy. The phase 3b ATTAIN-MAINTAIN trial suggests switching to once-daily oral therapy may help reduce weight regain when injectable treatment is discontinued.

13 May 2026

Adding GLP-1 drugs to behavioral interventions silences food noise

New research presented at this year's European Congress on Obesity in Istanbul, Turkey, shows that use of obesity drugs alongside behavioral interventions leads to a larger drop in so called 'food noise' than in those using the behavioral therapy alone.

13 May 2026

Rhein protects against intestinal injury in severe acute pancreatitis

Severe acute pancreatitis (SAP) remains one of the most formidable challenges in gastrointestinal emergency medicine.

13 May 2026

Could GLP-1 drugs help breast cancer patients live longer?

A large retrospective cohort study of adult female breast cancer patients found that GLP-1 receptor agonist use was associated with better all-cause survival and recurrence-free survival in patients with obesity or type 2 diabetes. The strongest associations were seen versus non-use in obesity and versus insulin or metformin in type 2 diabetes, while comparisons with SGLT2 inhibitors were less consistent and require further study.

12 May 2026

Researchers map the brain histamine system to understand mental health

New research, from King's College London and the University of Porto, has mapped the histamine system in the brain. Histamine, a molecule more commonly associated with allergies, plays a separate but poorly understood role in brain function.

12 May 2026

INDIGO Biosciences expands reporter assay capabilities with new Transrepression Assay Services

INDIGO Biosciences today announced the launch of its Transrepression Assay Services, expanding the company’s cell-based reporter assay capabilities for drug discovery teams studying pathway cross-talk, selective modulation, and transcription factor-mediated gene suppression.

From INDIGO Biosciences, Inc. 11 May 2026

Two leading heart risk tools pass a major global test

A multinational Nature Medicine validation study found that PREVENT and SCORE2 cardiovascular risk equations performed generally well across 6.4 million people from observational cohorts and randomized trials. The findings support broader use of these tools for CVD risk stratification, while highlighting the need for local calibration and more validation in underrepresented regions.

11 May 2026

Yale study finds garlic acts as birth control for mosquitoes

Garlic is not a substance that most people consider an aphrodisiac. It turns out that mosquitoes agree.

11 May 2026

Study links metabolic dysfunction to cognitive impairment in bipolar disorder

While they share similar depressive and cognitive symptoms, the biological underpinnings of bipolar disorder and major depressive disorder are distinct.

11 May 2026

Diabetes, weight-loss drugs not a perfect fit?

Type 2 diabetes affects millions of people worldwide and now a new international study, jointly led by Adelaide University, University of Oxford, ETH Zurich, and Stanford University, has found one in ten people may not be benefiting from common medications used to treat the condition.

11 May 2026

New study reveals how slow-growing cells drive breast cancer relapse

A new study by the Garvan Institute of Medical Research has uncovered a hidden mechanism explaining why breast cancer can return many years after successful treatment.

11 May 2026

Semaglutide shows sustained weight loss benefits in older adults

A new analysis of the STEP trails carried out by semaglutide manufacturer Novo Nordisk has analysed various trials to show the safety and efficacy of the obesity drug semaglutide in older adults (over 65 years), and found similar efficacy and safety as in the general trial populations .

11 May 2026

Daily orforglipron treatment reduces weight and blood sugar in seniors

A new analysis to be presented at this year's European Congress on Obesity (ECO 2026, Istanbul, Turkey, 12-15 May) examined daily oral orforglipron treatment for the treatment of obesity, with or without diabetes, in users aged 65 years and over, with results and a safety profile similar to that seen in the ATTAIN clinical trial programme population.

11 May 2026

Exercise or caffeine? Study finds neither clearly beats placebo for mental fatigue

Researchers compare the effects of caffeine and aerobic exercise on mental fatigue in adults.

10 May 2026

Tumors exploit peripheral nerves to support cancer growth and spread

Tumors do not communicate only with immune cells, blood vessels, and stromal tissue. A growing body of evidence suggests that cancer can also co-opt the nervous system, reshaping the tumor microenvironment in ways that support growth, invasion, immune escape, and therapeutic resistance.

10 May 2026

Researchers uncover how bacterial toxin damages colon lining cells to trigger cancer

Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor formation, potentially leading to colorectal cancer, by secreting a toxin that damages the lining of the colon.

8 May 2026